Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israël, Tel Aviv
Ronit El Hasid
38 années d'expérience
La clinique est certifiée :
| Israël | Turquie | Espagne | |
| Test sanguin avec marqueur tumoral | de $100 | de $100 | de $50 |
Bookimed ne facture pas de frais supplémentaires pour les prix des Test sanguin avec marqueur tumoral. Les tarifs sont issus des listes de prix officielles des cliniques. Vous payez directement à la clinique lors de votre arrivée pour votre Test sanguin avec marqueur tumoral.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans Test sanguin avec marqueur tumoral et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de Test sanguin avec marqueur tumoral.
Le médecin est le chef du département d'oncohématologie et d'oncologie pédiatrique à l'hôpital pour enfants Dana Dwek. Spécialisé dans les transplantations de moelle osseuse et de sang de cordon ombilical pour les enfants, le médecin a réalisé plus de 300 transplantations. Avec une forte présence académique, le médecin a publié 50 articles et présenté 40 rapports lors de diverses conférences médicales. Le médecin est membre de l'Association américaine d'hématologie et de la Société israélienne d'hémato-oncologie pédiatrique, et a exercé à l'hôpital City of Hope à Los Angeles et dans divers centres médicaux en Israël.<\/p>
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.
MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.
Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.